Morgan & Morgan Announces Investigation of MAP Pharmaceuticals
(NASDAQ: MAPP)
NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Morgan &
Morgan is investigating the Board of Directors of MAP
Pharmaceuticals Inc. ("MAP" or the "Company") (Nasdaq: MAPP) for
possible breaches of fiduciary duty and other violations of law
related to the sale of the Company to Allergan Inc.
If you are a current shareholder of MAP and are interested in
learning more about our MAP Pharmaceuticals merger investigation,
please contact George Pressly, Esq.
at 1 (800) 631-6234 or email George at
info@morgansecuritieslaw.com.
Under the terms of the transaction, MAP shareholders will
receive $25 for each share of MAP
stock they own. The transaction has a total approximate value of
$958 million. The investigation
concerns whether the MAP Board of Directors has breached its
fiduciary duties to act in the best interests of MAP shareholders
and to take all necessary steps to ensure that MAP shareholders
receive the maximum value readily available for their shares of MAP
common stock.
About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms.
In addition to securities fraud, the firm also practices in the
areas of antitrust, personal injury, consumer protection, overtime,
and product liability. All of the Firm's legal endeavors
are rooted in its core mission: provide investor and consumer
protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar
outcome.
Contact:
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44th Street
Suite 2001
New York, NY 10036
1-800-631-6234
info@morgansecuritieslaw.com
SOURCE Morgan & Morgan